Cidara Therapeutics Inc. ( (CDTX) ) has released its Q3 earnings. Here is a breakdown of the information Cidara Therapeutics Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cidara Therapeutics, Inc., a biotechnology company based in San Diego, is focused on developing drug-Fc conjugate therapeutics using its proprietary Cloudbreak platform, with a lead candidate aimed at preventing influenza.
In its latest earnings report, Cidara Therapeutics announced significant progress in its Phase 3 ANCHOR study for CD388, a non-vaccine influenza preventative therapeutic, which has been expanded to include a broader population. The company also highlighted a substantial financial milestone achieved with Janssen and a significant award from BARDA to support further development and manufacturing.
Key financial metrics from the third quarter of 2025 show a notable increase in cash reserves to $476.5 million, up from $196.2 million at the end of 2024. Despite this, the company reported a net loss of $83.2 million for the quarter, primarily due to increased R&D expenses related to the CD388 program. The FDA’s Breakthrough Therapy designation for CD388 and the expanded study population are expected to expedite the drug’s development and potential market approval.
Looking ahead, Cidara Therapeutics remains focused on completing the Phase 3 ANCHOR study by December 2025, with an interim analysis planned for early 2026. The company is optimistic about its financial position, which is expected to support the completion of its development program, and it continues to work towards bringing CD388 to market as a universal preventative for influenza.